LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-10.82%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$1.02B
AUM Growth
+$1.02B
(-11%)
Cap. Flow
+$84.4M
Cap. Flow
% of AUM
8.23%
Top 10 Holdings %
Top 10 Hldgs %
68.99%
Holding
83
New
24
Increased
8
Reduced
9
Closed
29
Top Buys
| 1 |
Design Therapeutics
DSGN
|
$81.7M |
| 2 |
Instil Bio
TIL
|
$46.3M |
| 3 |
Edgewise Therapeutics
EWTX
|
$34.3M |
| 4 |
Dyne Therapeutics
DYN
|
$24.8M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$23.9M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$44.2M |
| 2 |
Keros Therapeutics
KROS
|
$31.7M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$17.2M |
| 4 |
Avidity Biosciences
RNA
|
$17.1M |
| 5 |
Nkarta
NKTX
|
$13.9M |
Sector Composition
| 1 | Healthcare | 99.46% |
| 2 | Financials | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$62.7M
| $233M | 22.72% | 3,156,981 | – | – |
|
2
Olema Pharmaceuticals
OLMA
$375M
| $124M | 12.12% | 3,743,875 | – | – |
|
|
3
Design Therapeutics
DSGN
$315M
| $81.7M | 7.97% | +2,732,501 | New | +$81.7M |
|
|
4
Dyne Therapeutics
DYN
$1.92B
| $49.8M | 4.86% | 3,204,392 +1,600,000 | +100% | +$24.8M |
|
|
5
Instil Bio
TIL
$182M
| $46.3M | 4.52% | +1,846,850 | New | +$46.3M |
|
|
6
Nkarta
NKTX
$151M
| $41.5M | 4.05% | 1,260,877 -421,301 | -25% | -$13.9M |
|
|
FMTX
7
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $39.5M | 3.86% | 1,410,000 +10,000 | +0.7% | +$280K |
|
|
8
Edgewise Therapeutics
EWTX
$1.51B
| $34.3M | 3.35% | +1,056,812 | New | +$34.3M |
|
|
KNTE
9
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $29.1M | 2.84% | 934,602 +365,000 | +64% | +$11.4M |
|
10
Repare Therapeutics
RPTX
$71.7M
| $27.6M | 2.7% | 900,000 +223,106 | +33% | +$6.85M |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $24M | 2.35% | 200,000 +80,000 | +67% | +$9.62M |
|
|
BCYC
12
Bicycle Therapeutics
BCYC
$511M
| $23.9M | 2.33% | +800,000 | New | +$23.9M |
|
13
Athira Pharma
ATHA
$15.3M
| $18.6M | 1.82% | 1,010,812 +62,939 | +7% | +$1.16M |
|
14
BioXcel Therapeutics
BTAI
$59M
| $17.3M | 1.68% | 400,000 -30,000 | -7% | -$1.29M |
|
15
Cullinan Oncology
CGEM
$445M
| $17.2M | 1.68% | +413,458 | New | +$17.2M |
|
16
Cytokinetics
CYTK
$4.23B
| $16.3M | 1.59% | +700,000 | New | +$16.3M |
|
|
TPTX
17
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $13.2M | 1.29% | +140,000 | New | +$13.2M |
|
18
Cogent Biosciences
COGT
$1.69B
| $12.5M | 1.22% | 1,420,500 -500,000 | -26% | -$4.39M |
|
|
IMA
19
ImageneBio, Inc. Common Stock
IMA
$150M
| $11.9M | 1.16% | +419,853 | New | +$11.9M |
|
20
Aligos Therapeutics
ALGS
$73.3M
| $10.8M | 1.06% | 476,547 -130,001 | -21% | -$2.96M |
|
21
Kymera Therapeutics
KYMR
$2.95B
| $10.1M | 0.99% | 260,920 +150,000 | +135% | +$5.83M |
|
|
VINC
22
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $9.26M | 0.9% | +480,000 | New | +$9.26M |
|
|
CMPS
23
Compass Pathways
CMPS
$424M
| $9.21M | 0.9% | 250,000 -50,000 | -17% | -$1.84M |
|
24
Viridian Therapeutics
VRDN
$1.5B
| $9.19M | 0.9% | 550,000 | – | – |
|
|
ASLN
25
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $7.71M | 0.75% | +2,300,000 | New | +$7.71M |
|